Regulation of beta catenin signaling and parathyroid hormone anabolic effects in bone by the matricellular protein periostin
暂无分享,去创建一个
[1] R. Midura,et al. Parathyroid hormone suppresses osteoblast apoptosis by augmenting DNA repair. , 2009, Bone.
[2] T. Martin,et al. Osteoclast-derived activity in the coupling of bone formation to resorption. , 2005, Trends in molecular medicine.
[3] S. Ferrari,et al. Beta-arrestin2 regulates parathyroid hormone effects on a p38 MAPK and NFkappaB gene expression network in osteoblasts. , 2009, Bone.
[4] Jian Q. Feng,et al. periostin Null Mice Exhibit Dwarfism, Incisor Enamel Defects, and an Early-Onset Periodontal Disease-Like Phenotype , 2005, Molecular and Cellular Biology.
[5] R. Rizzoli,et al. β‐Arrestin2 Regulates the Differential Response of Cortical and Trabecular Bone to Intermittent PTH in Female Mice , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[6] G. Loots,et al. Parathyroid Hormone (PTH)–Induced Bone Gain Is Blunted in SOST Overexpressing and Deficient Mice , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[7] S. Reppe,et al. Periostin is a collagen associated bone matrix protein regulated by parathyroid hormone. , 2010, Matrix biology : journal of the International Society for Matrix Biology.
[8] A. Robling,et al. Anabolic and catabolic regimens of human parathyroid hormone 1-34 elicit bone- and envelope-specific attenuation of skeletal effects in Sost-deficient mice. , 2011, Endocrinology.
[9] S. Bao,et al. The multifaceted role of periostin in tumorigenesis , 2009, Cellular and Molecular Life Sciences.
[10] P. Roberson,et al. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. , 1999, The Journal of clinical investigation.
[11] M. Bouxsein,et al. Bone response to intermittent parathyroid hormone is altered in mice null for {beta}-Arrestin2. , 2005, Endocrinology.
[12] O. Leupin,et al. Does osteocytic SOST suppression mediate PTH bone anabolism? , 2010, Trends in Endocrinology & Metabolism.
[13] D. Goltzman,et al. Pretreatment with anticatabolic agents blunts but does not eliminate the skeletal anabolic response to parathyroid hormone in oophorectomized mice. , 2007, Endocrinology.
[14] D. Goltzman,et al. Co‐Treatment of PTH With Osteoprotegerin or Alendronate Increases Its Anabolic Effect on the Skeleton of Oophorectomized Mice , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[15] S. Reppe,et al. Gene expression profiles give insight into the molecular pathology of bone in primary hyperparathyroidism. , 2006, Bone.
[16] P. Roberson,et al. Intermittent parathyroid hormone administration counteracts the adverse effects of glucocorticoids on osteoblast and osteocyte viability, bone formation, and strength in mice. , 2010, Endocrinology.
[17] D. Bednarik,et al. Expression and function of periostin‐isoforms in bone , 2004, Journal of cellular biochemistry.
[18] P. Kostenuik,et al. Are Osteoclasts Needed for the Bone Anabolic Response to Parathyroid Hormone? , 2010, The Journal of Biological Chemistry.
[19] J. Bilezikian,et al. Differentiation and proliferation of periosteal osteoblast progenitors are differentially regulated by estrogens and intermittent parathyroid hormone administration. , 2008, Endocrinology.
[20] J. Bilezikian,et al. The cell biology of parathyroid hormone in osteoblasts , 2008, Current osteoporosis reports.
[21] Xiaoli Shen,et al. PTH-related protein modulates PC-3 prostate cancer cell adhesion and integrin subunit profile , 2003, Molecular and Cellular Endocrinology.
[22] Association of CDX1 binding site of periostin gene with bone mineral density and vertebral fracture risk , 2012, Osteoporosis International.
[23] R. Jilka. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. , 2007, Bone.
[24] R. Baron,et al. Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[25] M. Bouxsein,et al. β‐Arrestin2 Regulates RANKL and Ephrins Gene Expression in Response to Bone Remodeling in Mice , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[26] R. Lindsay,et al. A Novel Tetracycline Labeling Schedule for Longitudinal Evaluation of the Short‐Term Effects of Anabolic Therapy With a Single Iliac Crest Bone Biopsy: Early Actions of Teriparatide , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[27] L. Gelbert,et al. Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone (PTH) in rat bone: An analysis by DNA microarray , 2005, Journal of cellular biochemistry.
[28] K. Lau,et al. Up-regulation of the Wnt, Estrogen Receptor, Insulin-like Growth Factor-I, and Bone Morphogenetic Protein Pathways in C57BL/6J Osteoblasts as Opposed to C3H/HeJ Osteoblasts in Part Contributes to the Differential Anabolic Response to Fluid Shear* , 2006, Journal of Biological Chemistry.
[29] D. Notterman,et al. Determination of Dual Effects of Parathyroid Hormone on Skeletal Gene Expression in Vivo by Microarray and Network Analysis* , 2007, Journal of Biological Chemistry.
[30] R. Nissenson,et al. PTH Differentially Regulates Expression of RANKL and OPG , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[31] Mark L. Johnson,et al. Wnt/β-Catenin Signaling Is a Normal Physiological Response to Mechanical Loading in Bone* , 2006, Journal of Biological Chemistry.
[32] Hong Peng,et al. Interactions between cancer stem cells and their niche govern metastatic colonization , 2011, Nature.
[33] D. Fishman,et al. Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility. , 2002, Cancer research.
[34] M. Kraenzlin,et al. Parathyroid hormone analogues in the treatment of osteoporosis , 2011, Nature Reviews Endocrinology.
[35] F. Kuhlencordt,et al. [Primary hyperparathyroidism]. , 1979, Deutsche medizinische Wochenschrift.
[36] Xi He,et al. LDL receptor-related proteins 5 and 6 in Wnt/β-catenin signaling: Arrows point the way , 2004, Development.
[37] M. Foti,et al. The Matricellular Protein Periostin Is Required for Sost Inhibition and the Anabolic Response to Mechanical Loading and Physical Activity* , 2009, The Journal of Biological Chemistry.
[38] F. Natt,et al. Control of the SOST Bone Enhancer by PTH Using MEF2 Transcription Factors , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[39] M. Fukayama,et al. Periostin, a novel marker of intramembranous ossification, is expressed in fibrous dysplasia and in c-Fos-overexpressing bone lesions. , 2009, Human pathology.
[40] Nicola A Hanania,et al. Lebrikizumab treatment in adults with asthma. , 2011, The New England journal of medicine.
[41] L. Lanyon,et al. Wnt/β-Catenin Signaling Is a Component of Osteoblastic Bone Cell Early Responses to Load-bearing and Requires Estrogen Receptor α* , 2007, Journal of Biological Chemistry.